Headlands Technologies LLC Has $3.66 Million Holdings in Abbott Laboratories $ABT

Key Points

• Headlands Technologies increased its Abbott Laboratories stake by 74.3% in the second quarter, bringing its holdings to 40,367 shares valued at approximately $3.66 million. Institutional investors collectively own 75.18% of Abbott’s outstanding stock.
• Analyst sentiment remains positive, with Abbott receiving a “Moderate Buy” consensus rating and an average price target of $119.50. Several firms recently raised their targets, although Bank of America cut its objective to $102.
• Abbott exceeded quarterly expectations with $1.31 in earnings per share and $12.59 billion in revenue, up 13% year over year. The company also pays a quarterly dividend of $0.63 per share, equivalent to a 2.3% annual yield.

Headlands Technologies LLC lifted its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 74.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,367 shares of the healthcare product maker's stock after acquiring an additional 17,203 shares during the period. Headlands Technologies LLC's holdings in Abbott Laboratories were worth $3,663,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. J. Stern & Co. LLP boosted its position in shares of Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. Norges Bank bought a new position in shares of Abbott Laboratories in the fourth quarter valued at $2,938,892,000. Bank of America Corp DE acquired a new position in shares of Abbott Laboratories during the second quarter valued at about $1,603,607,000. Legal & General Group Plc acquired a new stake in shares of Abbott Laboratories in the 2nd quarter worth about $1,082,524,000. Finally, Flossbach Von Storch SE bought a new position in Abbott Laboratories in the 2nd quarter valued at about $902,938,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on ABT. Weiss Ratings upgraded Abbott Laboratories from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, August 6th. Bank of America reduced their price objective on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Wells Fargo & Company upped their price target on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an "overweight" rating in a research note on Friday, July 17th. Citigroup boosted their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a report on Friday, July 17th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Abbott Laboratories currently has an average rating of "Moderate Buy" and an average target price of $119.50.

Abbott Laboratories Trading Down 0.5%

Shares of ABT opened at $108.29 on Friday. The firm has a 50 day moving average price of $104.43 and a 200-day moving average price of $100.12. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The firm has a market cap of $187.38 billion, a price-to-earnings ratio of 35.05, a PEG ratio of 2.02 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm had revenue of $12.59 billion for the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the previous year, the business earned $1.26 earnings per share. The company's quarterly revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories's dividend payout ratio is currently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source